IMCR Q1 2024 Earnings — Immunocore Holdings plc Revenue & Financial Results | Market Cap Arena

IMCRImmunocore Holdings plc

$2B

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$71M+29.0% YoY

Gross Profit

$70M99.7% margin

Operating Income

-$26M-37.6% margin

Net Income

-$24M-34.7% margin

EPS (Diluted)

$-0.49

QoQ Revenue Growth

-0.4%

Cash Flow

Operating Cash Flow

-$5M

Free Cash Flow

-$5M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$994M

Total Liabilities

$634M

Stockholders' Equity

$360M

Cash & Equivalents

$833M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$71M	$55M	+29.0%
Gross Profit	$70M	$54M	+29.0%
Operating Income	-$26M	-$15M	-80.3%
Net Income	-$24M	-$19M	-25.6%

Revenue Segments

Collaboration Revenue

$160,000100%

Geographic Segments

UNITED STATES

$50M71%

Europe

$19M27%

Rest of World

$1M2%